Apple F S
Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, Minnesota 55415.
Am J Clin Pathol. 1992 Feb;97(2):217-26. doi: 10.1093/ajcp/97.2.217.
Early detection of AMI and reperfusion offers advantages to emergency department physicians when making diagnostic, therapeutic, and triage decisions. The measurement of serial CK-MB in serum remains the gold standard clinical laboratory test. A recommended enzyme ordering pattern scheme is described in Table 5. Rapidly available CK-MB results (two values separated by 30 to 180 minutes) may (1) prevent emergency department discharge of patients with AMI having nondiagnostic electrocardiographs and (2) allow more rapid use and assessment of thrombolytic therapy with AMI in patients not having diagnostic electrocardiographs. Technology no longer limits the availability of a stat CK-MB from the laboratory. However, each institution will have to assess the real value of a stat CK-MB. The future potential and clinical utility of troponin isoenzymes, CK isoforms, and myoglobin for diagnostic and therapeutic purposes still remain to be shown in real time settings.
急性心肌梗死(AMI)的早期检测和再灌注,对于急诊科医生在进行诊断、治疗和分诊决策时具有优势。血清中连续检测肌酸激酶同工酶MB(CK-MB)仍然是临床实验室检测的金标准。表5中描述了推荐的酶检测顺序方案。快速获得的CK-MB结果(两个值间隔30至180分钟)可能:(1)防止对心电图无诊断意义的AMI患者从急诊科出院;(2)对于心电图无诊断意义的AMI患者,能更快地使用和评估溶栓治疗。技术不再限制实验室快速提供CK-MB检测结果。然而,每个机构都必须评估快速检测CK-MB的实际价值。肌钙蛋白同工酶、CK同工型和肌红蛋白在诊断和治疗方面的未来潜力及临床实用性,仍有待在实际临床环境中得到证实。